Galectin Therapeutics Inc. (GALT)

[bradfor123]

Galectin Therapeutics (NASDAQ:GALT) had its price objective hosited by MLV & Co. from $20.00 to $27.00 in a report released on Wednesday, American Banking & Market News reports. MLV & Co. currently has a buy rating on the stock.

Galectin Therapeutics (NASDAQ:GALT) traded down 2.28% during mid-day trading on Wednesday, hitting $13.72. The stock had a trading volume of 184,871 shares. Galectin Therapeutics has a 52 week low of $3.19 and a 52 week high of $19.11. The stock has a 50-day moving average of $15.84 and a 200-day moving average of $11.53. The company’s market cap is $300.9 million.

Galectin Therapeutics (NASDAQ:GALT) last announced its earnings results on Friday, March 21st. The company reported ($0.15) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.18) by $0.03. On average, analysts predict that Galectin Therapeutics will post $-0.80 earnings per share for the current fiscal year.




Other equities research analysts have also recently issued reports about the stock. Analysts at Aegis raised their price target on shares of Galectin Therapeutics from $16.00 to $32.00 in a research note on Monday, February 10th. They now have a buy rating on the stock.

Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.

To view MLV & Co.’s full report, visit MLV & Co.’s official website.